Status: Recruiting
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Participants needed: 54
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Icahn School of Medicine at Mount SinaiUpdated: Aug 13, 2026Locations: 1
Eligibility criteria
Pathologic (histology or cytology) confirmed diagnosis of epithelial ovarian can... [+37]